Pureland Global Venture

Pureland divides its capital across two separate funds. Fund I focuses on secondary markets, using derivatives-based income strategies and algorithmic trading to preserve capital. Fund II is an impact fund that makes direct venture investments in medical-technology companies.

The firm lists an advisor team of Eiffel Sun, Hong Shaoming, Rayson Tan and Zhang Heng on its website. There are no publicly named executive officers such as a CEO or CIO, and decision-making authority has not been disclosed.

Pureland started as a single-family office in 2014 and has since expanded into a private investment group managing two distinct funds. The firm does not disclose whether it continues to operate family capital alongside external commitments, so it is best described as an asset manager with family-office origins.

Venture investments are made through Fund II, which is designated as an impact fund targeting medical-technology opportunities. The firm does not specify a preferred stage, though its venture arm is broadly described as pursuing early-stage and growth-stage medtech companies.

The firm has not disclosed its posture on co-investments. No portfolio companies, co-investors or fund partnerships are publicly identified, so its approach to working with external managers remains unconfirmed.